Insider · CIK 0001600865
James R Neal
Files at PCSA (Processa Pharmaceuticals, Inc.), AKTX (Akari Therapeutics Plc), PKBO (Peak Bio, Inc.). First filing -, latest -.
James R Neal files SEC Form 4 as director at PCSA (Processa Pharmaceuticals, Inc.), and also at AKTX (Akari Therapeutics Plc), PKBO (Peak Bio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James R Neal has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Warrants to purchase American Depositary Shares ("ADRs")derivative | +2,473 | - | - | 2,473 | Mar 16, 2026 |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Pre-Funded Warrants to purchase ADRsderivative | +2,473 | $0.40 | $999 | 2,473 | Mar 16, 2026 |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Warrants to purchase ADRsderivative | +3,093 | - | - | 3,093 | Mar 16, 2026 |
| Dec 16, 2025 | AKTX Akari Therapeutics Plc | POpen-market purchase Pre-Funded Warrants to purchase ADRsderivative | +3,093 | $0.40 | $1,250 | 3,093 | Mar 16, 2026 |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +100,000 | $0.00 | $0 | 100,000 | Oct 3, 2025 |
| Oct 1, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Oct 3, 2025 |
| Sep 3, 2024 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stockderivative | +31,206 | $0.00 | $0 | 36,275 | Sep 18, 2025 |
| Jul 24, 2025 | PCSA Processa Pharmaceuticals, Inc. | AGrant or award Restricted Stockderivative | +175,299 | $0.00 | $0 | 206,505 | Jul 28, 2025 |
| Mar 20, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Mar 24, 2025 |
| Mar 20, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.00 | $0 | 225,000 | Mar 24, 2025 |
| Mar 6, 2025 | AKTX Akari Therapeutics Plc | AGrant or award American Depositary Shares representing Ordinary Shares | +4,464 | $1.12 | $5,000 | 36,271 | Mar 10, 2025 |
| Mar 6, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Series A Warrants (Right to Buy)derivative | +4,464 | $1.12 | $5,000 | 4,464 | Mar 10, 2025 |
| Mar 6, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Series B Warrants (Right to Buy)derivative | +4,464 | $1.12 | $5,000 | 4,464 | Mar 10, 2025 |
| Jan 9, 2025 | AKTX Akari Therapeutics Plc | AGrant or award Ordinary Shares, par value $0.0001 per share | +8,000,000 | $0.00 | $4,800 | 32,216,000 | Jan 10, 2025 |
| Dec 23, 2024 | AKTX Akari Therapeutics Plc | AGrant or award Ordinary Shares, par value $0.0001 per share | +2,000,000 | $0.00 | $1,000 | 24,216,000 | Dec 26, 2024 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | CConversion Common Stock | +37,850 | - | - | 37,850 | Nov 18, 2024 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | DDisposition to issuer Common Stock | -37,850 | - | - | 0 | Nov 18, 2024 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | CConversion Convertible Notesderivative | - | - | - | 0 | Nov 18, 2024 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | DDisposition to issuer Warrant (Right to Purchase)derivative | -33,340 | - | - | 0 | Nov 18, 2024 |
| Nov 14, 2024 | PKBO Peak Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -500,000 | $0.00 | $0 | 0 | Nov 18, 2024 |
Questions about James R Neal
Answered from the filings on this page, as of the latest one.
Is James R Neal buying or selling?
James R Neal has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James R Neal's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James R Neal has 0.
Where does James R Neal file Form 4?
James R Neal has filed Form 4 at PCSA (Processa Pharmaceuticals, Inc.); AKTX (Akari Therapeutics Plc); PKBO (Peak Bio, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.